神隆 (1789.TW)

28.60 +0.50 (+1.78%) 收市：01:30PM CST

神隆

No. 1, Nan-Ke 8th Road
Southern Taiwan Science Park Shan-Hua
Tainan City 74144
Taiwan
886 6 505 2888
https://www.scinopharm.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Chih-Hsien Lo	Chairman & General Chief Strategy Officer	無	無	1957
Ms. Li-An Lu	President & CEO	無	無	無
Ms. Chih-Hui Lin	Acting Financial Off., Senior Director of Acct., Acct. Off., Acting Spokesperson & Corp. Gov. Off.	無	無	無
Mr. Ling-Hsiao Lien	Vice-President of Operations	無	無	無
Dr. Li-Chiao Chang Chemistry, Ph.D.	VP of R&D Division and Chief Scientific Officer	無	無	無
Mr. Jason Chen	Director of Human Resources & Admin	無	無	無
Dr. Ching-Wen Lin B.S, M.S, Ph.D.	VP of Marketing & Sales and Chief Strategy Officer	無	無	無
Mr. Shun Yang Lin	Director of Corporate Development	無	無	無

截止 為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 TWD。

描述

ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells cGMP active pharmaceutical ingredients (API) to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, Taiwan, and internationally. The company offers small molecular drugs, complex natural molecules and derivatives, synthesis services for biochemistry molecules, such as peptides and nucleic acids; generic API manufacturing services; and outsourcing services. It also provides CRAM services, such as chemistry skill, analytical and regulatory, chemical process development, clinical drug substance, and consulting services for the development and manufacturing of clinical, small-scale, and commercial-stage APIs and intermediates. In addition, the company develops peptide synthesis technologies. Further, the company develops and manufactures western medicines and other chemical materials, albumin medicines, oligonucleotide medicines, injections, and new small molecule drugs, as well as provides biological technology services and technical services. It has a strategic alliance with Baxter International Inc. to develop, manufacture, and commercialize of antiemetic drug in chemotherapy for cancer. ScinoPharm Taiwan, Ltd. was incorporated in 1997 and is headquartered in Tainan City, Taiwan.

公司管治

截至 無 止，神隆 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。